Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer
ConclusionsThe CAPOX50 regimen did not improve local control, disease-free survival and overall survival in the ACCORD12 trial. Late toxicities did not differ between treatment arms.
Source: Annals of Oncology - Category: Cancer & Oncology Source Type: research
More News: Adenocarcinoma | Bleeding | Cancer | Cancer & Oncology | Colorectal Cancer | Eloxatin | Erectile Dysfunction | Incontinence | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Pain | Rectal Cancers | Statistics | Study | Toxicology | Xeloda